These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 23403727)

  • 1. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer.
    Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3.
    Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3].
    Riedinger JM; Goussot V; Desmoulins I; Lorgis V; Coutant C; Beltjens F; Lizard S; Fumoleau P
    Bull Cancer; 2016 May; 103(5):434-43. PubMed ID: 26969424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
    Samy N; Ragab HM; El Maksoud NA; Shaalan M
    Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3.
    Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
    Br J Cancer; 1996 Oct; 74(7):1126-31. PubMed ID: 8855986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients.
    Molina R; Jo J; Filella X; Zanón G; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM
    Anticancer Res; 1999; 19(4A):2551-5. PubMed ID: 10470193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
    Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
    BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer.
    D'Alessandro R; Roselli M; Ferroni P; Mariotti S; Spila A; Aloe S; Carone MD; Abbolito MR; Carlini S; Perri P; Ricciotti A; Botti C; Conti F; Vici P; Chiappetta NR; Cognetti F; Buonomo O; Guadagni F
    Breast Cancer Res Treat; 2001 Jul; 68(1):9-19. PubMed ID: 11678313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.
    Stieber P; Nagel D; Blankenburg I; Heinemann V; Untch M; Bauerfeind I; Di Gioia D
    Clin Chim Acta; 2015 Aug; 448():228-31. PubMed ID: 26160053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer.
    Petersen ER; Sørensen PD; Jakobsen EH; Madsen JS; Brandslund I
    Clin Chem Lab Med; 2013 Jul; 51(7):1483-92. PubMed ID: 23420288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.
    Di Gioia D; Dresse M; Mayr D; Nagel D; Heinemann V; Stieber P
    Clin Chim Acta; 2015 Feb; 440():16-22. PubMed ID: 25444743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
    Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
    Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value.
    Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM
    Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse.
    Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J
    Oncology; 1994; 51(6):491-6. PubMed ID: 7970492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast Cancer.
    Shao Y; Sun X; He Y; Liu C; Liu H
    PLoS One; 2015; 10(7):e0133830. PubMed ID: 26207909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
    Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
    Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study.
    Guadagni F; Ferroni P; Carlini S; Mariotti S; Spila A; Aloe S; D'Alessandro R; Carone MD; Cicchetti A; Ricciotti A; Venturo I; Perri P; Di Filippo F; Cognetti F; Botti C; Roselli M
    Clin Cancer Res; 2001 Aug; 7(8):2357-62. PubMed ID: 11489813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated levels of serum tumor markers CA 15-3 and CEA are prognostic factors for diagnosis of metastatic breast cancers.
    Lee JS; Park S; Park JM; Cho JH; Kim SI; Park BW
    Breast Cancer Res Treat; 2013 Oct; 141(3):477-84. PubMed ID: 24072270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of CEA for detection of distant metastases in newly diagnosed breast cancer: comparison with CA 15-3.
    Maccio G; Goussot V; Berriolo-Riedinger A; Riedinger JM
    Ann Biol Clin (Paris); 2017 Aug; 75(4):431-441. PubMed ID: 28751288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.